● Recruiting

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

Condition: HPV Infection · HPV-Related Carcinoma · HPV-Related Intraepithelial Neoplasia · Sponsor: Shanghai Bovax Biotechnology Co., Ltd.

PhasePhase 2

Planned participants330

Who can joinAll sexes, 9 Years to 45 Years

Healthy volunteersYes

About this study

To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.

This description comes directly from the study's public registry record.

Talk to the study team

Dabin Liang · +86 15977783657 · gxirb2018@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

Nanning, Guangxi, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06756269